

AAIC 2026 Presentation & Poster List

	Presentation / Poster	Author	Institution
1	The Potential of Alzheimer's Plasma Biomarkers for Mimicking Tau PET-based Disease Staging	Lotte A. de Koning	Amsterdam UMC
2	Brain-derived pTau Isoforms Exhibit High Intra-individual Stability Among 124 Neurobiomarkers	Isabel M. Houtkamp	Amsterdam UMC
3	Causal Discovery of Alzheimer's Disease Biomarkers Using Fast Causal Inference Algorithm	Natalia Gazman	King's College London
4	Evaluating a Future In Vitro Diagnostic pTau217 Plasma Assay for the Detection of Amyloid Pathology in Primary and Secondary Care Settings	Annunziata Di Domenico	Roche
5	Head-to-head Comparison of Plasma pTau217, GFAP and NfL Assessments on Two Fully Automated Analysis Platforms	Emma Gummesson	University of Gothenburg
6	Plasma Brain-derived Phospho-tau: From Pre-clinical to Clinical Cohorts	Ashvini Keshavan	University College London / Queen Square Institute of Neurology
7	Plasma Brain-derived pTau217/BD-tau Ratio Improves Discrimination of A β -PET and Tau-PET Positivity Compared With pTau217 Alone	James Doecke	CSIRO
8	Plasma pTau217 Dynamics Across Major Platforms in Early Alzheimer's Disease: Trajectories Anchored to Estimated Amyloid PET Onset	Ramiro Eduardo Rea Reyes	University of Wisconsin–Madison
9	Preserving Functional Network Segregation Is Associated With Stable Plasma pTau217 Level and Cognitive Reserve in the General Population	Weiyi Zeng	German Center for Neurodegenerative Diseases, Bonn
10	Proteomic Profiles of Cognitive Decline and Resilience by pTau217 Status	Atiana Sogorb-Esteve	Reina Sofia Foundation Alzheimer Centre
11	Scalable and Accessible Approach for Biological-cognitive Profiling of Alzheimer's Disease	Eero Vuoksima	University of Helsinki
12	Systematic Baseline Shifts in Plasma pTau217 Require Cohort-specific Calibration	Kyungsung Lee	Emocog Inc.
13	Systemic Medication Exposure and Biomarkers of Preclinical Alzheimer's Disease	Frida Lener	University of Gothenburg
14	The Clinical Application of Plasma Biomarkers for Alzheimer's Disease in a Hong Kong Cohort With Cognitive Impairment	Yat Fung Shea	Queen Mary Hospital
15	Understanding Blood-based Biomarker Positivity Rates in Undifferentiated High-risk Geriatric Patients in the Emergency Department	Saket Saxena	Cleveland Clinic
16	The Temporal Sequence of Presymptomatic Plasma Biomarker Changes in Autosomal Dominant Alzheimer's Disease	Christopher Belder	Adelaide University School of Medicine
17	Simplifying Ultra-Sensitive Fluid Biomarker Detection: Next-Generation Alzheimer's Blood Testing with the Ella™ System	Yoav Noam	University Ulm
18	ADAPT Stage 1 — Assessing Plasma p-tau217 Cut-points Against Quantitative Amyloid PET Centiloids Versus Visual Reads	Laura Rizzo	UK Dementia Research Institute / Imperial College London
19	APOE Genotype Modifies Relationships Between Plasma AD Biomarkers and Serum Anti-A β 42 Autoantibodies in Adults With Down Syndrome	Yajing Zhou	King's College London
20	Brain Age Gap Interacts With Plasma pTau217 to Predict Cognitive Decline	Elaine Yi Li Teo	Duke-NUS Medical School, Singapore
21	Cognitively Unimpaired APOE4 Carriers With Cerebral Hyperperfusion Exhibit Better Cognitive Function	Melanie Quiring	University of Southern California
22	Comparative Analysis of Heterophile Antibody Interference in the Fujirebio Lumipulse pTau217 and Roche Elecsys pTau217 Assays	Joshua Bornhorst	Mayo Clinic

AAIC 2026 Presentation & Poster List

	Presentation / Poster	Author	Institution
23	Establishing Valid Discrete and Continuous Reference Intervals for BD-tau and p-tau217	Isabella DiBerardino	University of British Columbia
24	Novel Plasma Biomarkers Track Cognitive Performance Using Digital Testing	Sofia Toniolo	University of Oxford
25	Relationship of Plasma p-tau217 and Neurodegeneration in Early-onset Alzheimer's Disease	Alexandra Touroutoglou	Massachusetts General Hospital / Harvard Medical School
26	Sandbox: NHS-embedded AI Platform for Multimodal Biomarkers and Scalable Blood Sampling in Dementia	Hayley Holt	Prima Mente
27	Synaptic VAMP2 and SNAP25 and pTau217 Levels in Brain and Plasma	Sanda O. Tome	KU Leuven
28	The CA1 Hippocampal Subfield Mediates the Association of Plasma NfL and pTau217 With Verbal Memory in Older Adults at Risk for Dementia	Nicole Espinoza	University of Sydney
29	The Relationship Between pTau217 and Tau PET Visual Read Positivity Categories in Cognitively Normal Individuals	Julie Elisabeth Oomens	Wisconsin Alzheimer's Disease Research Center / University of Wisconsin School of Medicine and Public Health
30	Earlier Menopause Exacerbates Associations Between APOE4 and Alzheimer's Disease Risk	Madeline Wood Alexander	University of Toronto
31	Plasma pTau217 Associations With Amyloid and Tau PET Differ Between Down Syndrome and Neurotypical Adults During AD Progression	Elizabeth Batchelar	University of Wisconsin-Madison
32	Alzheimer's Biological Staging with Blood-Based Biomarkers: Insights from Beckman Coulter and the AIBL Study	James Doecke	CSIRO
33	Etalanutug Reduces Tau Tangle-specific Plasma e-MTBR-tau243 in DIAD While Increasing Plasma pTau and t-tau in Healthy and DIAD	Kristin Wildsmith	Eisai
34	28-year Depressive Symptom Trajectories and Plasma Phosphorylated Tau-217	Toni T. Saari	University of Helsinki
35	Assessing Social Connectedness as a Source of Cognitive Resilience Among Indigenous Elders	Kyle Coniff	University of Wisconsin-Madison
36	Brain-derived pTau217 Outperforms pTau181 and Brain-derived Tau Assays for Identifying Alzheimer's Disease in MCI/Mild Dementia	Johanna Mitterreiter	Siemens Healthineers
37	Bringing Alzheimer's Disease Biomarkers to General Practice: The BRIDGE Study Protocol and Baseline Data	Sarah Gregory	Scottish Brain Sciences
38	Combining Cognitive Screening With ALZpath pTau217 Levels to Identify Cognitive Impairment in a Primary Care Setting	Robin C. Hilsabeck	University of Texas at Austin
39	Data-driven Plasma Biomarker Discovery to Improve the Prediction of Cognitive Impairment in an African American Cohort	Lindsey A. Kuchenbecker	Mayo Clinic Florida
40	Exploring Plasma Biomarkers of Dementia in Middle-aged and Older Autistic Adults	Dani Christensen	University of Florida
41	Greater Hypoxemia During REM Sleep Is Linked to Decreased Basal Forebrain Volume in Older Adults Who Are pTau217 Positive	Aaron Lam	University of Sydney
42	Influence of Demographic and Health Factors on Clinical Vulnerability or Resilience to Amyloid Pathology Assessed by Plasma p-tau217	Nya N. Nicholson	University of Pittsburgh
43	Intraoperative Cortical Brain Biopsy Supports Plasma-derived pTau217 as Marker of Brain Amyloid Pathology	Aram Aslanyan	UCL Queen Square Institute of Neurology
44	Menopause Timing Relates to a Tau- and Growth Factor-enriched CSF Proteomic Composite in Older Postmenopausal Women	Anna M. Vandebunte	University of California San Diego

AAIC 2026 Presentation & Poster List

	Presentation / Poster	Author	Institution
45	Optimizing Referral Pathways for Alzheimer's Biomarker Diagnostics Using Nurse-led Decision Tool	Kayla van der Ploeg	Lawson Research Institute
46	Plasma pTau217 Measurements in Cerebral Amyloid Angiopathy	Waad Alshammari	University of British Columbia
47	Prospective Association of Midlife ADRD Biomarkers With Hippocampal Neurite Density: Evidence From Child Health and Development Studies	Isha Mhatre-Winters	University of Georgia
48	Qualification of NULISaseq CNS Biomarker Panel for Alzheimer's Disease Research	Kristen A. Russ	Indiana University
49	The Mediating Effect of Glymphatic Efficiency on the Relationship Between Choroid Plexus Volume and Cognition in Alzheimer's Disease	Nicole Isabella Tan	National Neuroscience Institute, Singapore
50	Undiagnosed Alzheimer's Pathology in Cardiovascular Patients and Its Implications for Prevention: BROADWAY Trial Dissected	John J.P. Kastelein	NewAmsterdam Pharma
51	Acute Food Intake Rapidly Decreases Plasma p-tau217 Levels in Individuals With and Without Alzheimer's Pathology	Hanna Huber	University of Bonn
52	The Future of Precision Care in Alzheimer's Disease: From Diagnosis Through Management With Blood and Imaging Biomarkers	Nicholas Ashton	Banner Research Institute
53	Evidence Supporting Preclinical AD as an Optimal Stage for Intervention With Trontinemab	Reisa Sperling	Harvard Medical School
54	Interim Long-term Biomarker Results From the Trontinemab Open-label Extension of the Phase Ib/IIa Brainshuttle AD Study	Henrik Zetterberg	Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Mölndal, Sweden
55	A Brief Digital Symbol-coding Task Outperforms Clinical Benchmarks for Alzheimer's Trial Pre-enrichment	Brian Murphy	Cumulus Neuroscience
56	Blood-based Biomarker Signatures In A Population At Risk Of Alzheimer's Disease: Interim Results Of The PREDICTOM Study	Johanna Mitterreiter	Siemens Healthineers; Germany
57	APOE4 Status Modulates the Association Between Alzheimer's Disease Blood Biomarkers and White Matter Hyperintensity Volume	Michael Malek-Ahmadi	Rice University
58	At Risk Populations and Mixed Pathology: Updates From Wisconsin Registry for Alzheimer's Prevention — WRAP	Ramiro Eduardo Rea Reyes	University of Wisconsin School of Medicine and Public Health / ADRC
59	Benchmarking the Diagnostic Accuracies of Plasma p-tau205 and p-tau212 Against p-tau217 in Alzheimer's Disease	Anuradha Sehrawat	University of Pittsburgh
60	Clinical Utility of Plasma Biomarkers of Alzheimer's Disease	Juli Singer	University of Pittsburgh
61	Early Second Language Experience Protects Medial Temporal Cortex Against Alzheimer's Biomarkers in Aging	Beate Shumann-Werner	Otto von Guericke University Magdeburg
62	Evaluation of Diagnostic Utility of Key Plasma p-tau217 Immunoassays for Detecting Amyloid-beta Pathology in a Southeast Asian Cohort	Christopher Chen	National University of Singapore
63	Head-to-head Comparison of Plasma p-tau217 Associations With MK6240 and Flortaucipir Tau PET	Pamela C. Ferreira	University of Pittsburgh
64	IST-NDDP: An Istanbul-based Real-world Data Platform for Neurodegenerative Disease Research and Biomarker Validation	Erdinc Dursun	Istanbul University-Cerrahpasa
65	Plasma pTau217 Mediates the Association Between Basal Forebrain Free Water and Sleep Quality in Early Alzheimer's Disease	Futao Chen	Nanjing Drum Tower Hospital
66	Precise and Ultrasensitive Detection of Blood-based Biomarkers for Alzheimer's Disease Using Automated Ella System	Joe Dunbar	Bio-Techne

AAIC 2026 Presentation & Poster List

	Presentation / Poster	Author	Institution
67	Prevalence of Modifiable Risk Factors in Older Adults From the Population-based Study REAL AD	Laura Stankeviciute	University of Gothenburg
68	R-FIRE (Rural Firefighter Investigation of Risk & Exposure): Brain Health	Michelle K. Lupton	QIMR Berghofer, Brisbane, Australia
69	Remote Cognitive Assessment and Plasma pTau217 for Preclinical Alzheimer's Disease Risk Stratification in the REAL AD Study	Frederick Ohman	University of Gothenburg
70	Short Remote Cognitive Screening for Early Identification of Alzheimer's Disease in the Population Without Dementia	Karin Lohi	University of Helsinki / Institute for Molecular Medicine Finland
71	Short-interval Reliability of Blood-based Biomarkers Measured Using NULISaseq CNS Disease Panel	Millie Beament	University College London
72	Utility of Plasma NfL and pTau217 in an Australian Memory Clinic	Jia Zheng	Royal Melbourne Hospital
73	White Matter Microstructural Integrity Predicts Future Plasma pTau217 Change	McKenna E. Williams	University of California San Diego
74	Blood Biomarker Assays Demonstrate Strong Rule-in Performance for Identifying Cognitively Unimpaired AD	Samantha Burnham	Eli Lilly and Company, Indianapolis, IN, USA
75	Blood-based Proteomic Signatures of SuperAgers: Evidence for Reduced Mixed Proteinopathy Burden	Adam Martersteck	University of Chicago
76	Amyloid PET Classification Accuracy for Elecsys Cobas pTau217 in Cognitively Unimpaired Older Adults Among the Six Common APOE Genotypes	Michael Malek-Ahmadi	Banner Alzheimer's Institute
77	Longitudinal Plasma p-tau217: What Is Meaningful Change?	Nicholas Ashton	Banner Health
78	Association Between STOP-BANG Questionnaire and Alzheimer's Disease Blood-based Biomarkers in the Brazilian Cog-Aging Cohort	Ana Carolina Oliveira Sinzato	Universidade Federal de Minas Gerais
79	Clinical Implementation of Plasma pTau217 Testing for Alzheimer's Disease: A Canadian Experience With Over 900 Tests	Pankaj Kumar	University of British Columbia
80	Diagnostic Performance of Roche Elecsys and ALZpath Simoa pTau217 Assays in a Taiwanese Alzheimer's Disease Cohort	Yung-Shuan Lin	Taipei Veterans General Hospital
81	Elevated Plasma p-tau217 Levels in Older Adults With Enlarged Perivascular Spaces	Arunima Kapoor	University of California, Irvine
82	Machine Learning-derived Plasma Proteomic Signatures for 10-year Prediction of Incident Dementia	Ramon Casanova	Wake Forest University School of Medicine, Biostatistics and Data Science
83	Older African American APOE4 Carriers Found to Have Higher Plasma p-tau217 and Greater Risk for Amyloid-positive Status	Gilda E. Ennis	University of Wisconsin-Madison
84	Plasma Biomarker Associations With Hippocampal Atrophy	Alpana Singh	Banner Sun Health Research Institute
85	pTau217 Prediction of Cognitive Change in Late Life — A Latent Change Modeling Study	Luis Castro de Araujo	Virginia Commonwealth University
86	The Association Between Plasma p-tau217, Sleep, and Speech Rate Over Time in Cognitively Unimpaired Older Adults	Phoebe Crumpton	University of Wisconsin-Madison